Proteomic analysis of Alzheimer's disease cerebrospinal fluid reveals alterations associated with <i>APOE</i> ε4 and atomoxetine treatment.

ABSTRACT: Alzheimer's disease (AD) is currently defined by the aggregation of amyloid-β (Aβ) and tau proteins in the brain. Although biofluid biomarkers are available to measure Aβ and tau pathology, few markers are available to measure the complex pathophysiology that is associated with these two cardinal neuropathologies. Here, we characterized the proteomic landscape of cerebrospinal fluid (CSF) changes associated with Aβ and tau pathology in 300 individuals using two different proteomic technologies-tandem mass tag mass spectrometry and SomaScan. Integration of both data types allowed for generation of a robust protein coexpression network consisting of 34 modules derived from 5242 protein measurements, including disease-relevant modules associated with autophagy, ubiquitination, endocytosis, an

SUBMITTER: Dammer EB 

PROVIDER: S-EPMC12175351 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature